Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Acadia: Dataset Suggests no Negative Impact on Motor Symptoms or Cognition; no Deaths in Remlifanserin Treatment Arms

THOMSON REUTERS
·
Sep 24

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 Radiant Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

THOMSON REUTERS
·
Sep 24

Acadia: Narrowly Missed Primary Endpoint of Saps H+D (p=0.0603) with Significance (Nominal) on Key Secondary Endpoint of CGI-S-ADP (p=0.0077)

THOMSON REUTERS
·
Sep 24

Acadia Pharmaceuticals - on Aug 24, Court Preliminarily Approves Settlement of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing

THOMSON REUTERS
·
Sep 12

Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Sep 03

ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank

TIPRANKS
·
Aug 25

Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating

MT Newswires Live
·
Aug 25

U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials

Reuters
·
Aug 25

Acadia Pharmaceuticals Gets European Approval of Rett Syndrome Drug Daybu

Dow Jones
·
Aug 24

EU Approves Acadia’s DAYBU for Rett Syndrome Symptoms in Patients 5 and Older

Reuters
·
Aug 24

European Commission Approves Daybu® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

THOMSON REUTERS
·
Aug 24

Acadia Pharmaceuticals - Receives Ec Marketing Authorization for Daybu for Rett Syndrome

THOMSON REUTERS
·
Aug 24

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TIPRANKS
·
Aug 18

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)

Simply Wall St.
·
Aug 18

UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating

MT Newswires Live
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Aug 12

Acadia Pharmaceuticals Inc. : Needham Raises Target Price to $41 from $38

THOMSON REUTERS
·
Aug 12

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

MT Newswires Live
·
Aug 10

ACADIA Pharmaceuticals (ACAD) Gets a Buy from Citi

TIPRANKS
·
Aug 10